Initial phase I trials with anti PDCD1 or anti-PD-L1 mAbs have shown considerable promise, with response rates of 18–28% and 10–17%, respectively, in patients with advanced pre-treated melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma [35]. Here, CD274 is linked to melanoma.